Mega‐dose decitabine conditioning and prophylactic donor lymphocyte infusion for patients with relapsed/refractory AML with active disease at the time of allogeneic haematopoietic cell transplantation: A multicenter prospective phase II study

Documenti analoghi

• Clinical features and prognostic model for viral encephalitis after allogeneic haematopoietic stem cell transplantation
  di: Jin Wu, et al.
  Pubblicazione: (2024)
• Outcomes and risk factors of second allogeneic haematopoietic stem cell transplantation in patients with relapsed haematological malignancy after first transplantation
  di: Xiaolu Zhu, et al.
  Pubblicazione: (2025)
• Monitoring the KMT2A gene post‐chemotherapy independently predicts the relapse and survival risk after allogeneic haematopoietic stem cell transplantation
  di: Jing Liu, et al.
  Pubblicazione: (2025)
• Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation
  di: Francesca Perutelli, et al.
  Pubblicazione: (2025)
• Venetoclax plus azacitidine with or without homoharringtonine followed by allogeneic haematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukaemia: A multicentre cohort study
  di: Yiling Ye, et al.
  Pubblicazione: (2025)